TNF and metabolic dysfunction-associated steatohepatitis: NASH patients treated with eicosapentaenoic acid (EPA) or n-3 PUFAs, a mixture of EPA and docosahexaenoic acid, exhibited improvements in hepatic steatosis and necroinflammation in humans and rats with NASH, probably due to the reduction of hepatic TNFα expression and improvement of insulin sensitivity [41–43].